

# Report to the Meeting of the

**BOD 116/2017**

(Agenda item: 16)

# Oxford Health NHS Foundation Trust

# Board of Directors

**27 September 2017**

**Research and Development Board Report**

**For: Information**

**Executive Summary**

The past six months has seen the start of the Oxford Heath National Institute of Health Research (NIIHR) Biomedical Research Centre (BRC), with the award of £12.8 million over the next five years. OHFT was the only completely new BRC awarded in the 2016 funding round and only the second to specialize in mental health and dementia, although there are other BRCs with such themes embedded in their comprehensive BRCs. The funding will enable the Trust to increase infrastructure to support translational experimental medical research and to leverage additional funding into mental health and dementia. The BRC will be under the Directorship of Professor John Geddes

It has been announced that the NIHR Community Healthcare Medtech and In Vitro Diagnostic Co-operative application, submitted earlier this year has been successful, with Oxford Health NHS FT hosting the award - £1.24 million over five years, starting in January 2018. The Oxford MIC is one of 11 newly funded NIHR. It will bring together and synergise experienced health researchers, end users, and clinical experts skilled in the development and evaluation of diagnostic tests. The MIC will be led by the Clinical Director, Professor Chris Butler.

The renewal of the NIHR Clinical Research Facility (CRF) hosted by Oxford University Hospitals NHS Foundation Trust (OUH) has also commenced within the last six month, with continuing research activity growing at the Warenford CRF to support experimental medicine and work progressing on identifying research space at the John Radcliffe Hospital. The CRF will be a key element in supporting the BRC. The CRF will continue under the Directorship of Professor John Geddes.

The Oxford NIHR Collaboration in Leadership in Applied Health Research and Care (CLAHRC) led by Professor Richard Hobbs continues to make good progress against its objectives and generate impact in the form of academic publications, patient benefit and cost savings within the NHS.

The NIHR Diagnostic Evidence Co-operative (DEC), led by Dr Gail Hayward is moving into its final few months of funding (December 2017) of generating information on the clinical and cost effectiveness of in vitro diagnostics to help disease diagnosis.

Oxford Health continues to remain within the top three trusts for recruitment into mental health and dementia studies. Work continues to development mechanisms to increase the number of non-mental health community studies.

Following the announcement in February of reduced funding, the Oxford Academic Health Science Network (AHSN) has undertaken the restructuring of Best Care. The Trust continues to support three themes; Early intervention, Anxiety and Depression and Dementia. The AHSN is led by Prof Gary Ford.

It is expected that R&D will meet its expected contributions to overheads and break even on external funding streams.

A new Research Management Group is providing a value asset in steering the strategic and scientific direction of research undertaken within Oxford Health NHS FT and its partners by bringing together key stakeholders from the various NIHR infrastructures, AHSC, AHSN, University of Oxford on a monthly basis. The group are also being provided with a dashboard of activity on a quarterly basis.

**Governance Route/Approval Process**

This report is a biannual report for information to the Board

**Recommendation**

The Board is asked to note the report.

**Author and Title: Emma Stratful and John Geddes**

**Lead Executive Director: Mark Hancock**